Atea Pharmaceuticals (AVIR) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.41

Estimate

-$0.56

Surprise

+26.1%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Atea Pharmaceuticals (AVIR) reported a narrower loss than forecast — diluted EPS of -$0.41 against the -$0.56 estimate (a 26.1% beat on a still-unprofitable quarter).

• Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7 — benzinga, 2026-08-13
• Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) Estimate — benzinga, 2026-08-12

TrendMatrix currently rates AVIR Sell at 5.2/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +26.1% surprise compares with a -6.3% four-quarter average. Next scheduled report: 2026-11-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$5.43

Price target

$8.00

Stop

$5.05

Upside to target

+47.3%

Reward-to-risk

3.2:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$435.5M

P/E (fwd)

-3.7

52-week range

$2.78–$6.45

Off 52-week high

15.8%

RSI (14)

74

Volume vs avg

0.55×

Score today

5.2/10